Loading…
Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?
Purpose High cholesterol content of erythrocyte membranes (CEM) levels is present in patients with acute coronary syndromes (ACS). Intraplaque hemorrhage and erythrocyte lysis contribute to the deposition of cholesterol on the atherosclerotic plaque and to plaque rupture. With the present study we a...
Saved in:
| Published in: | Cardiovascular drugs and therapy 2009-12, Vol.23 (6), p.471-480 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c400t-2521fdfcd1bb439fa6099a8c1114cb918ed4bdfe1a10895f5a28afb1cdc56c0b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c400t-2521fdfcd1bb439fa6099a8c1114cb918ed4bdfe1a10895f5a28afb1cdc56c0b3 |
| container_end_page | 480 |
| container_issue | 6 |
| container_start_page | 471 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 23 |
| creator | Tziakas, Dimitrios N. Chalikias, Georgios K. Stakos, Dimitrios Tentes, Ioannis K. Thomaidi, Adina Chatzikyriakou, Sofia Mitrousi, Konstantina Kortsaris, Alexandros X. Carlos Kaski, Juan Boudoulas, Harisios Konstantinides, Stavros |
| description | Purpose
High cholesterol content of erythrocyte membranes (CEM) levels is present in patients with acute coronary syndromes (ACS). Intraplaque hemorrhage and erythrocyte lysis contribute to the deposition of cholesterol on the atherosclerotic plaque and to plaque rupture. With the present study we assessed the effect of statin therapy on CEM levels, a novel marker of coronary artery disease (CAD) instability during a 1-year follow-up in CAD patients.
Methods
212 consecutive eligible (158 men, 62 ± 10 years) patients undergoing diagnostic coronary angiography for the assessment of angina pectoris were assessed. The study population comprised of 84 chronic stable angina (CSA) patients and 128 ACS patients. All study participants were commenced on statin treatment in equipotent doses and were followed for up to 1 year (at − 1, − 3, − 6 and − 12 months).
Results
Repeated measurements analysis of variance after appropriate adjustment showed a significant decrease (
p
|
| doi_str_mv | 10.1007/s10557-009-6202-7 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733613569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1935446231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-2521fdfcd1bb439fa6099a8c1114cb918ed4bdfe1a10895f5a28afb1cdc56c0b3</originalsourceid><addsrcrecordid>eNp1kUuLFDEURoMoTk_rD3AjQZBZ1Zib1CNZSdO0DxgfOM46pFI30xmqK22SUnrrLzdDNw4IrrLI-e79uIeQF8AugbHuTQLWNF3FmKpaznjVPSILaDpRdbyGx2TBFGeV4Kw9I-cp3bGSUUo-JWegpJBt3S3I7-tssp_oTULqE12lFKw3GQf6y-ctNfTa307eeWumTL_hMNvsw0RLYr0NI6aMMYx0HaaMBQiObuIhb2Owh4z0E-76aCZMl3RFP4efONKvI_qQY9h7SzfOoc1vn5EnzowJn5_eJbl5t_m-_lBdfXn_cb26qmzNWK54w8ENzg7Q97VQzrRMKSMtANS2VyBxqPvBIRhgUjWuMVwa14MdbNNa1osluTjO3cfwYy7V9c4ni-NYGoY56U6IFkTTqkK--oe8C3OcSjnNQcha1qopEBwhG0NKEZ3eR78z8aCB6Xs9-qhHFz36Xk9ZsCQvT4PnfofDQ-LkowCvT4BJ1oyuXM_69JfjnCsuOS8cP3KpfE23GB8a_n_7H_M2qOI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213848495</pqid></control><display><type>article</type><title>Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?</title><source>Springer Nature</source><creator>Tziakas, Dimitrios N. ; Chalikias, Georgios K. ; Stakos, Dimitrios ; Tentes, Ioannis K. ; Thomaidi, Adina ; Chatzikyriakou, Sofia ; Mitrousi, Konstantina ; Kortsaris, Alexandros X. ; Carlos Kaski, Juan ; Boudoulas, Harisios ; Konstantinides, Stavros</creator><creatorcontrib>Tziakas, Dimitrios N. ; Chalikias, Georgios K. ; Stakos, Dimitrios ; Tentes, Ioannis K. ; Thomaidi, Adina ; Chatzikyriakou, Sofia ; Mitrousi, Konstantina ; Kortsaris, Alexandros X. ; Carlos Kaski, Juan ; Boudoulas, Harisios ; Konstantinides, Stavros</creatorcontrib><description>Purpose
High cholesterol content of erythrocyte membranes (CEM) levels is present in patients with acute coronary syndromes (ACS). Intraplaque hemorrhage and erythrocyte lysis contribute to the deposition of cholesterol on the atherosclerotic plaque and to plaque rupture. With the present study we assessed the effect of statin therapy on CEM levels, a novel marker of coronary artery disease (CAD) instability during a 1-year follow-up in CAD patients.
Methods
212 consecutive eligible (158 men, 62 ± 10 years) patients undergoing diagnostic coronary angiography for the assessment of angina pectoris were assessed. The study population comprised of 84 chronic stable angina (CSA) patients and 128 ACS patients. All study participants were commenced on statin treatment in equipotent doses and were followed for up to 1 year (at − 1, − 3, − 6 and − 12 months).
Results
Repeated measurements analysis of variance after appropriate adjustment showed a significant decrease (
p
< 0.001) in CEM content during follow up. CEM levels were decreasing at each time point (1 month : 100 ug/mg 95%CI 94.3–105.6, 3 months : 78.1 ug/mg 95%CI 73.2–83, 6 months : 67.2 ug/mg 95%CI 63.1–71.2, 1 year : 45.3 ug/mg 95%CI 42.2–48.3) compared to admission (112.1 ug/mg 95% CI 105.9–118.3) and to all previous measurements.
Conclusions
The present study showed, that use of statins is associated with a reduction in CEM, an emerging marker of clinical instability and plaque vulnerability in CAD patients. The pleiotropic effects of statins at the cell membrane level represent a promising novel direction for research in CAD.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-009-6202-7</identifier><identifier>PMID: 19838647</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Acute Coronary Syndrome - drug therapy ; Biological and medical sciences ; Cardiology ; Cardiology. Vascular system ; Cardiovascular system ; Cholesterol - blood ; Coronary Angiography ; Coronary heart disease ; Disorders of blood lipids. Hyperlipoproteinemia ; Erythrocyte Membrane - drug effects ; Heart ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Metabolic diseases ; Middle Aged ; Pharmacology. Drug treatments</subject><ispartof>Cardiovascular drugs and therapy, 2009-12, Vol.23 (6), p.471-480</ispartof><rights>Springer Science+Business Media, LLC 2009</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-2521fdfcd1bb439fa6099a8c1114cb918ed4bdfe1a10895f5a28afb1cdc56c0b3</citedby><cites>FETCH-LOGICAL-c400t-2521fdfcd1bb439fa6099a8c1114cb918ed4bdfe1a10895f5a28afb1cdc56c0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22292822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19838647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tziakas, Dimitrios N.</creatorcontrib><creatorcontrib>Chalikias, Georgios K.</creatorcontrib><creatorcontrib>Stakos, Dimitrios</creatorcontrib><creatorcontrib>Tentes, Ioannis K.</creatorcontrib><creatorcontrib>Thomaidi, Adina</creatorcontrib><creatorcontrib>Chatzikyriakou, Sofia</creatorcontrib><creatorcontrib>Mitrousi, Konstantina</creatorcontrib><creatorcontrib>Kortsaris, Alexandros X.</creatorcontrib><creatorcontrib>Carlos Kaski, Juan</creatorcontrib><creatorcontrib>Boudoulas, Harisios</creatorcontrib><creatorcontrib>Konstantinides, Stavros</creatorcontrib><title>Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><addtitle>Cardiovasc Drugs Ther</addtitle><description>Purpose
High cholesterol content of erythrocyte membranes (CEM) levels is present in patients with acute coronary syndromes (ACS). Intraplaque hemorrhage and erythrocyte lysis contribute to the deposition of cholesterol on the atherosclerotic plaque and to plaque rupture. With the present study we assessed the effect of statin therapy on CEM levels, a novel marker of coronary artery disease (CAD) instability during a 1-year follow-up in CAD patients.
Methods
212 consecutive eligible (158 men, 62 ± 10 years) patients undergoing diagnostic coronary angiography for the assessment of angina pectoris were assessed. The study population comprised of 84 chronic stable angina (CSA) patients and 128 ACS patients. All study participants were commenced on statin treatment in equipotent doses and were followed for up to 1 year (at − 1, − 3, − 6 and − 12 months).
Results
Repeated measurements analysis of variance after appropriate adjustment showed a significant decrease (
p
< 0.001) in CEM content during follow up. CEM levels were decreasing at each time point (1 month : 100 ug/mg 95%CI 94.3–105.6, 3 months : 78.1 ug/mg 95%CI 73.2–83, 6 months : 67.2 ug/mg 95%CI 63.1–71.2, 1 year : 45.3 ug/mg 95%CI 42.2–48.3) compared to admission (112.1 ug/mg 95% CI 105.9–118.3) and to all previous measurements.
Conclusions
The present study showed, that use of statins is associated with a reduction in CEM, an emerging marker of clinical instability and plaque vulnerability in CAD patients. The pleiotropic effects of statins at the cell membrane level represent a promising novel direction for research in CAD.</description><subject>Acute Coronary Syndrome - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular system</subject><subject>Cholesterol - blood</subject><subject>Coronary Angiography</subject><subject>Coronary heart disease</subject><subject>Disorders of blood lipids. Hyperlipoproteinemia</subject><subject>Erythrocyte Membrane - drug effects</subject><subject>Heart</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kUuLFDEURoMoTk_rD3AjQZBZ1Zib1CNZSdO0DxgfOM46pFI30xmqK22SUnrrLzdDNw4IrrLI-e79uIeQF8AugbHuTQLWNF3FmKpaznjVPSILaDpRdbyGx2TBFGeV4Kw9I-cp3bGSUUo-JWegpJBt3S3I7-tssp_oTULqE12lFKw3GQf6y-ctNfTa307eeWumTL_hMNvsw0RLYr0NI6aMMYx0HaaMBQiObuIhb2Owh4z0E-76aCZMl3RFP4efONKvI_qQY9h7SzfOoc1vn5EnzowJn5_eJbl5t_m-_lBdfXn_cb26qmzNWK54w8ENzg7Q97VQzrRMKSMtANS2VyBxqPvBIRhgUjWuMVwa14MdbNNa1osluTjO3cfwYy7V9c4ni-NYGoY56U6IFkTTqkK--oe8C3OcSjnNQcha1qopEBwhG0NKEZ3eR78z8aCB6Xs9-qhHFz36Xk9ZsCQvT4PnfofDQ-LkowCvT4BJ1oyuXM_69JfjnCsuOS8cP3KpfE23GB8a_n_7H_M2qOI</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Tziakas, Dimitrios N.</creator><creator>Chalikias, Georgios K.</creator><creator>Stakos, Dimitrios</creator><creator>Tentes, Ioannis K.</creator><creator>Thomaidi, Adina</creator><creator>Chatzikyriakou, Sofia</creator><creator>Mitrousi, Konstantina</creator><creator>Kortsaris, Alexandros X.</creator><creator>Carlos Kaski, Juan</creator><creator>Boudoulas, Harisios</creator><creator>Konstantinides, Stavros</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?</title><author>Tziakas, Dimitrios N. ; Chalikias, Georgios K. ; Stakos, Dimitrios ; Tentes, Ioannis K. ; Thomaidi, Adina ; Chatzikyriakou, Sofia ; Mitrousi, Konstantina ; Kortsaris, Alexandros X. ; Carlos Kaski, Juan ; Boudoulas, Harisios ; Konstantinides, Stavros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-2521fdfcd1bb439fa6099a8c1114cb918ed4bdfe1a10895f5a28afb1cdc56c0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acute Coronary Syndrome - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular system</topic><topic>Cholesterol - blood</topic><topic>Coronary Angiography</topic><topic>Coronary heart disease</topic><topic>Disorders of blood lipids. Hyperlipoproteinemia</topic><topic>Erythrocyte Membrane - drug effects</topic><topic>Heart</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tziakas, Dimitrios N.</creatorcontrib><creatorcontrib>Chalikias, Georgios K.</creatorcontrib><creatorcontrib>Stakos, Dimitrios</creatorcontrib><creatorcontrib>Tentes, Ioannis K.</creatorcontrib><creatorcontrib>Thomaidi, Adina</creatorcontrib><creatorcontrib>Chatzikyriakou, Sofia</creatorcontrib><creatorcontrib>Mitrousi, Konstantina</creatorcontrib><creatorcontrib>Kortsaris, Alexandros X.</creatorcontrib><creatorcontrib>Carlos Kaski, Juan</creatorcontrib><creatorcontrib>Boudoulas, Harisios</creatorcontrib><creatorcontrib>Konstantinides, Stavros</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tziakas, Dimitrios N.</au><au>Chalikias, Georgios K.</au><au>Stakos, Dimitrios</au><au>Tentes, Ioannis K.</au><au>Thomaidi, Adina</au><au>Chatzikyriakou, Sofia</au><au>Mitrousi, Konstantina</au><au>Kortsaris, Alexandros X.</au><au>Carlos Kaski, Juan</au><au>Boudoulas, Harisios</au><au>Konstantinides, Stavros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><stitle>Cardiovasc Drugs Ther</stitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>23</volume><issue>6</issue><spage>471</spage><epage>480</epage><pages>471-480</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>Purpose
High cholesterol content of erythrocyte membranes (CEM) levels is present in patients with acute coronary syndromes (ACS). Intraplaque hemorrhage and erythrocyte lysis contribute to the deposition of cholesterol on the atherosclerotic plaque and to plaque rupture. With the present study we assessed the effect of statin therapy on CEM levels, a novel marker of coronary artery disease (CAD) instability during a 1-year follow-up in CAD patients.
Methods
212 consecutive eligible (158 men, 62 ± 10 years) patients undergoing diagnostic coronary angiography for the assessment of angina pectoris were assessed. The study population comprised of 84 chronic stable angina (CSA) patients and 128 ACS patients. All study participants were commenced on statin treatment in equipotent doses and were followed for up to 1 year (at − 1, − 3, − 6 and − 12 months).
Results
Repeated measurements analysis of variance after appropriate adjustment showed a significant decrease (
p
< 0.001) in CEM content during follow up. CEM levels were decreasing at each time point (1 month : 100 ug/mg 95%CI 94.3–105.6, 3 months : 78.1 ug/mg 95%CI 73.2–83, 6 months : 67.2 ug/mg 95%CI 63.1–71.2, 1 year : 45.3 ug/mg 95%CI 42.2–48.3) compared to admission (112.1 ug/mg 95% CI 105.9–118.3) and to all previous measurements.
Conclusions
The present study showed, that use of statins is associated with a reduction in CEM, an emerging marker of clinical instability and plaque vulnerability in CAD patients. The pleiotropic effects of statins at the cell membrane level represent a promising novel direction for research in CAD.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>19838647</pmid><doi>10.1007/s10557-009-6202-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 2009-12, Vol.23 (6), p.471-480 |
| issn | 0920-3206 1573-7241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733613569 |
| source | Springer Nature |
| subjects | Acute Coronary Syndrome - drug therapy Biological and medical sciences Cardiology Cardiology. Vascular system Cardiovascular system Cholesterol - blood Coronary Angiography Coronary heart disease Disorders of blood lipids. Hyperlipoproteinemia Erythrocyte Membrane - drug effects Heart Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Male Medical sciences Medicine Medicine & Public Health Metabolic diseases Middle Aged Pharmacology. Drug treatments |
| title | Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect? |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A20%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statin%20Use%20is%20Associated%20with%20a%20Significant%20Reduction%20in%20Cholesterol%20Content%20of%20Erythrocyte%20Membranes.%20A%20Novel%20Pleiotropic%20Effect?&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Tziakas,%20Dimitrios%20N.&rft.date=2009-12-01&rft.volume=23&rft.issue=6&rft.spage=471&rft.epage=480&rft.pages=471-480&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1007/s10557-009-6202-7&rft_dat=%3Cproquest_cross%3E1935446231%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-2521fdfcd1bb439fa6099a8c1114cb918ed4bdfe1a10895f5a28afb1cdc56c0b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213848495&rft_id=info:pmid/19838647&rfr_iscdi=true |